Suresh Mendpara, MD
Hematology & Oncology · Wadsworth, OHNPI 1427036391
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $214 of the $242 with a category attached, or 88.4%. 7 manufacturers reported payments, led by Novartis at 31.2% of the total. Reporting peaked in 2022 at $88 and has fallen 58.9% since, to $36 in 2025. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 8 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$76
- Bayer$72
- Coloplast$30
- Daiichi Sankyo Inc.$18
- Incyte Corporation$18
- E.r. Squibb & Sons, L.L.C.$16
- plus $12 from 1 others
What the payments were for
- Food & beverage$21488%
- Education$2812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 2 | $76 |
| Bayer | 1 | $72 |
| Coloplast | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Gilead | 1 | $12 |
How this compares
$242 in reported general payments places this provider in the 15th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 28 | $444,775 |
| ImbruvicaIbrutinib | 24 | $384,420 |
| WeliregBelzutifan | 12 | $327,885 |
| Lenalidomide | 18 | $268,656 |
| XtandiEnzalutamide | 15 | $214,674 |
| LynparzaOlaparib | 13 | $199,283 |
| CalquenceAcalabrutinib Maleate | 13 | $190,282 |
| TagrissoOsimertinib Mesylate | 11 | $187,337 |
| EliquisApixaban | 106 | $93,082 |
| Abiraterone Acetate | 30 | $62,732 |
| XareltoRivaroxaban | 21 | $27,194 |
| Ondansetron Hcl | 41 | $2,984 |
| Anastrozole | 86 | $1,879 |
| Hydroxyurea | 75 | $1,530 |
| Letrozole | 51 | $1,295 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Wadsworth
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.